Trials / Terminated
TerminatedNCT02204293
Canakinumab for Treatment of Adult-onset Still's Disease
Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Charite University, Berlin, Germany · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canakinumab | Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously. |
| DRUG | Placebo | Matching placebo administered subcutaneously. |
Timeline
- Start date
- 2012-06-21
- Primary completion
- 2018-05-05
- Completion
- 2018-05-05
- First posted
- 2014-07-30
- Last updated
- 2020-08-07
- Results posted
- 2020-08-07
Locations
14 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02204293. Inclusion in this directory is not an endorsement.